Last reviewed · How we verify

NCT06060561

Genetic Testing to Improve Management of Patients Undergoing Breast Biopsy

Suspended Last updated 29 August 2025
What this trial tests

trial testing Non-Interventional Study in Breast Carcinoma in 500 participants. Suspended.

Timeline
30 May 2023
Primary endpoint
30 June 2028
30 June 2028

Quick facts

Lead sponsorMayo Clinic
StatusSuspended
Study typeOBSERVATIONAL
Enrollment500
Start date30 May 2023
Primary completion30 June 2028
Estimated completion30 June 2028
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, female only, with Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates genetic testing to improve risk assessment and advance efforts to develop precision management for breast cancer by studying saliva samples for genotyping and evaluate associations with pathologic diagnoses and detailed pathologic and radiologic features.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06060561.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing